Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
A total of 9 abstracts presented at the 18th Annual European Neuroendocrine Tumor Society (ENETS) Conference showcasing new data across the patient pathway in neuroendocrine tumors Latest data from the Phase II CLARINET FORTE study are the subject of an oral presentation showing q...
Ipsen S.A. (IPSEY) Q4 2020 Earnings Conference Call February 11, 2021, 08:30 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - EVP and Group CFO Conference Call Participants Matthew Weston - Credit Suisse Michael Leuchten - UBS Emily Field - Barclays Sarita Kapila - JPMorgan ...
Solid full year 2020 results in a COVID-19 environment, with Group sales growth of 3.0% 1 and Core Operating margin at 32.0% 2021 guidance of Group sales growth greater than 4.0% at constant currency and Core Operating margin greater than 30.0% of the sales 2021 ...
With a median follow-up of two years, Cabometyx ® in combination with Opdivo ® continues to demonstrate superior progression-free survival, overall survival and objective response rate compared to sunitinib 1 Patients treated with Cabometyx ® in comb...
10 abstracts to be presented showcasing promising data across multiple genitourinary cancers, including renal cell carcinoma (RCC) and prostate cancer 1-11 Highlights include extended follow-up and health-related quality of life data from the pivotal CheckMate -9ER trial, furt...
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005966/en/ Gwenan White, Executive Vice President, Communications and Public Affairs, Ipsen (Photo: Business Wire) Ipsen (Euronext: IPN...
Ipsen (IPSEY) announces results from new analyses of Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport (abobotulinumtoxinA [aboBoNT-A]) in five patient populations.The new analyses included trials to assess treatment intervals over repeat cycles of...
Analyses of pivotal study data of Dysport ® reveal a large proportion of study patients did not require retreatment for at least 12 weeks (and at least 16 weeks for pediatric upper limb spasticity) This new analysis concluded that Dysport ® is associated with a l...
Thinly traded nano cap Merrimack Pharmaceuticals ([[MACK]] +42.2%) rallies on a whopping 309x surge in volume in apparent response to a corporate presentation yesterday by Ipsen S.A. ([[IPSEY]]).In the R&D section, management presented an update (slide 42) on Onivyde (irinotecan liposome ...
Focus on core therapeutic areas of Oncology, Rare Disease and Neuroscience Commitment to invest in R&D supported by SG&A efficiencies Priority on External Innovation strategy to build sustainable pipeline for future growth Regulatory News: Ipsen (Euronext: IP...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...